Emixustat vs placebo
- Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to… 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 503 participantsLow
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to geographic atrophy compared with placebo (low certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
It is very uncertain whether lutein with or without zeaxanthin changes adverse effects compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether vitamin E changes progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Vitamin E showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
The review found no eligible studies for this question.
Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).
It is very uncertain whether vitamin E changes adverse effects compared with placebo (very low certainty).
The review found no eligible studies for this question.